Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;38(2):325-348.
doi: 10.1016/j.ncl.2020.01.003. Epub 2020 Mar 2.

Medical and Surgical Treatments for Dystonia

Affiliations
Review

Medical and Surgical Treatments for Dystonia

H A Jinnah. Neurol Clin. 2020 May.

Abstract

The dystonias are a large and heterogenous group of disorders characterized by excessive muscle contractions leading to abnormal postures and/or repetitive movements. Their clinical manifestations vary widely, and there are many potential causes. Despite the heterogeneity, helpful treatments are available for the vast majority of patients. Symptom-based therapies include oral medications, botulinum toxins, and surgical interventions. For some subtypes of dystonia, specific mechanism-based treatments are available. Advances in understanding the biological basis for many types of dystonia have led to numerous recent clinical trials, so additional treatments are likely to become available in the very near future.

Keywords: Blepharospasm; Botulinum toxin; Deep brain stimulation; Meige syndrome; Oromandibular dystonia; Therapy; Torticollis.

PubMed Disclaimer

Conflict of interest statement

Disclosure H.A. Jinnah has active or recent grant support from the US government (National Institutes of Health), private philanthropic organizations (the Benign Essential Blepharospasm Research Foundation, Cure Dystonia Now) and industry (Cavion Therapeutics, Ipsen Pharmaceuticals, Retrophin Inc., and Revance). Dr H.A. Jinnah has also served on advisory boards or as a consultant for Allergan Inc., CoA Therapeutics, Medtronic Inc., and Retrophin Inc. He has received honoraria or stipends for lectures or administrative work from the American Academy of Neurology, the American Neurological Association, the Dystonia Medical Research Foundation, the International Neurotoxin Society, the International Parkinson’s Disease and Movement Disorders Society, The Parkinson’s Disease Foundation, and Tyler’s Hope for a Cure. Dr H.A. Jinnah serves on the Scientific Advisory Boards for several private foundations including the Benign Essential Blepharospasm Research Foundation, Cure Dystonia Now, the Dystonia Medical Research Foundation, the Tourette Association of America, and Tyler's Hope for a Cure. He also is principal investigator for the Dystonia Coalition, which has received the majority of its support through NIH grants NS116025 and NS065701 from the National Institutes of Neurological Disorders and Stroke and previously grant TR 001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences. The Dystonia Coalition has received additional material or administrative support from industry sponsors (Allergan Inc. and Merz Pharmaceuticals) as well as private foundations (The American Dystonia Society, Beat Dystonia, The Benign Essential Blepharospasm Foundation, Cure Dystonia Now, Dystonia Europe, Dystonia Inc., Dystonia Ireland, The Dystonia Medical Research Foundation, The Foundation for Dystonia Research, The National Spasmodic Dysphonia Association, and The National Spasmodic Torticollis Association).

Figures

Figure 1.
Figure 1.. Classification of the dystonias.
The many types of dystonia are classified according to two axes. The first axis relates to clinical features. The main factors important for clinical classification include age at onset, body distribution, temporal features, and whether or not dystonia is combined with other neurological or medical problems. The main factors important for etiological classification include whether the disorder is associated with relevant brain pathology, and whether the disorder is acquired or inherited. However, a large proportion of cases remain idiopathic.
Figure 2.
Figure 2.. Diagnostic approach.
This algorithm provides a basic strategy for the diagnostic approach to most patients with dystonia. The initial step is to determine whether the disorder being considered is a type of dystonia, or something that may mimic dystonia. The next step is to use the history and examination to delineate the dystonia syndrome, using the main clinical features used for classification. The third step is to consider potential etiologies.
Figure 3.
Figure 3.. Treatment approach.
This algorithm provides a basic strategy for the therapeutic approach to most patients with dystonia. The clinical and etiological evaluations are important, because They influence optimal treatments strategies. For children, diagnostic testing is essential because there is a greater likelihood of discovering a treatable cause. When a cause cannot be found, a trial of oral levodopa is conducted to rule out dopa-responsive dystonia. For adults, dystonia is more often idiopathic, so extensive workup is often not needed. Instead, the approach depends on body distribution. For the focal dystonias, botulinum toxins provide a useful starting point. Oral medications can be used, but often are not well-tolerated. Those who have unsatisfactory responses can be offered surgery. Generalized dystonias or dystonia combined with other neurological problems in adults requires some additional diagnostic testing, to disclose a potentially treatable cause.

References

    1. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013;28:863–873. - PMC - PubMed
    1. Balint B, Mencacci NE, Valente EM, et al. Dystonia. Nat Rev Dis Primers. 2018;4:25. - PubMed
    1. Jinnah HA, Albanese A. The new classification for the dystonias: Why was it needed and how was it accomplished? Mov Disord Clin Pract. 2014;1:280–284. - PMC - PubMed
    1. Fung VS, Jinnah HA, Bhatia K, Vidailhet M. Assessment of the patient with dystonia: An update on dystonia syndromes. Mov Disord. 2013;28:889–898. - PMC - PubMed
    1. Jinnah HA, Sun YV. Dystonia genes and their biological pathways. Neurobiol Dis. 2019;in press. - PubMed